Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Chartmill

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
99 100 Next >
Outset Medical (NASDAQ:OM) Jumps 19% on Q2 Revenue Beat, HCA Deal ↗
Via Chartmill
Tickers OM
NerdWallet (NASDAQ:NRDS) Surges After Q3 Guidance Beats Estimates, Offsetting Mixed Q2 Results ↗
Via Chartmill
Tickers NRDS
Cloudflare (NYSE:NET) Jumps 16% on Q2 Beat and Strong Full-Year Guidance ↗
Via Chartmill
Tickers NET
MicroVision (NASDAQ:MVIS) Rises on Commercial Pipeline Progress Despite Q2 Revenue Miss ↗
Via Chartmill
Tickers MVIS
Morgan Stanley Direct Lending (NYSE:MSDL) Q2 NII Matches Estimates, Revenue Slightly Below ↗
Via Chartmill
Tickers MS MSDL
Maravai Lifesciences (NASDAQ:MRVI) Shares Slide Despite Q2 Beat as Full-Year Revenue Outlook Weighs ↗
Via Chartmill
Tickers MRVI
WM Technology (NASDAQ:MAPS) Misses Q2 Estimates and Guides to Sequential Revenue Decline ↗
Via Chartmill
Tickers MAPS
Main Street Capital (NYSE:MAIN) Reports Mixed Q2 Results: Revenue Beats, EPS Slightly Misses ↗
Via Chartmill
Tickers MAIN
Lineage Cell Therapeutics (NYSEARCA:LCTX) Slips on Q2 Revenue Miss, but EPS In Line and Pipeline Advances ↗
Via Chartmill
Tickers LCTX
Innodata (NASDAQ:INOD) Smashes Q2 Estimates on Revenue and Profit, Stock Surges ↗
Via Chartmill
Tickers INOD
Inogen (NASDAQ:INGN) Falls as Revenue Misses and Full-Year Guidance Trails Estimates ↗
Via Chartmill
Tickers INGN
Indie Semiconductor (NASDAQ:INDI) Shares Surge as Q2 Results Top Estimates ↗
Via Chartmill
Tickers INDI
Granite Ridge Resources (NYSE:GRNT) Beats Q2 Earnings Estimates, Revenue Slightly Misses ↗
Via Chartmill
Tickers GRNT
Gevo Inc (NASDAQ:GEVO) Gains on Narrower Q2 Loss and Doubled 2026 EBITDA Outlook ↗
Via Chartmill
Tickers GEVO
Gladstone Investment (NASDAQ:GAIN) Beats Fiscal Q1 Estimates on Strong Investment Income ↗
Via Chartmill
Tickers GAIN
Genpact (NYSE:G) Slips After Inline Q2 Results ↗
Via Chartmill
Tickers G
CareTrust REIT (NYSE:CTRE) Beats Q2 Estimates and Raises Full-Year Guidance ↗
Via Chartmill
Tickers CTRE
Corvus Pharmaceuticals (NASDAQ:CRVS) Misses Q2 Loss Estimates as Clinical-Stage Spending Continues ↗
Via Chartmill
Tickers CRVS
Concentra (NYSE:CON) Beats Q2 Estimates and Raises Guidance, but Shares Stay Flat ↗
Via Chartmill
Tickers CON
Celldex Therapeutics (NASDAQ:CLDX) Q2 EPS Beat Overshadowed by Revenue Miss and Prurigo Nodularis Discontinuation ↗
Via Chartmill
Tickers CLDX
Consensus Cloud Solution (NASDAQ:CCSI) Tumbles on Weak Outlook Despite In-Line Q2 ↗
Via Chartmill
Tickers CCSI
Amphastar Pharmaceuticals (NASDAQ:AMPH) Beats Q2 Earnings Estimates, Shares Rise After Hours ↗
Via Chartmill
Tickers AMPH
AMN Healthcare (NYSE:AMN) Surges After Blowout Q2 Earnings Beat ↗
Via Chartmill
Tickers AMN
American International Group (NYSE:AIG) Beats Q2 Earnings, But Revenue Misses ↗
Via Chartmill
Tickers AIG
Senseonics Holdings (NASDAQ:SENS) Jumps on Q2 Revenue Beat and Raised Full-Year Guidance ↗
Via Chartmill
Tickers SENS
ResMed (NYSE:RMD) Q4 Results Inline with Estimates; Stock Slips 1.9% ↗
Via Chartmill
Tickers ASX:RMD RMD
Ouster (NASDAQ:OUST) Drops on Soft Q3 Guidance Despite Q2 Beat ↗
Via Chartmill
Tickers OUST
Octave Specialty Group (NYSE:OSG) Revenue Beats but Adjusted Loss Widens in Q2 ↗
Via Chartmill
Tickers OSG
Omada Health (NASDAQ:OMDA) Soars on Q2 Beat, Record Margins, and Raised Guidance ↗
Via Chartmill
Tickers OMDA
Nerdy (NYSE:NRDY) Slides After Q2 Report as Weak Guidance Overshadows Results ↗
Via Chartmill
Tickers NRDY
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.